We are glad to announce the publication of our scientific paper on 4P004 “Liraglutide, a Glucagon-Like Peptide 1 receptor agonist, exerts analgesic,anti-inflammatory and anti-degradative actions in osteoarthritis ” , Meurotet al. in Scientific Reports (2022).
In this paper, we demonstrate that Liraglutide, an agonist of GLP-1 receptor, ameliorates OA-associated pain, possesses anti-inflammatory and analgesic properties.
Since 2016, 4P-Pharma’s and 4MovingBiotech’s teams have developed 4P004, a potential novel first-in-class disease modifying osteoarthritis drug (DMOAD) candidate.
A phase I clinical trial on patients will be conducted in 2022.